TTNP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TTNP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Titan Pharmaceuticals's Revenue per Share for the three months ended in Dec. 2023 was $0.00.
During the past 12 months, Titan Pharmaceuticals's average Revenue per Share Growth Rate was -98.90% per year. During the past 3 years, the average Revenue per Share Growth Rate was -96.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was -92.70% per year. During the past 10 years, the average Revenue per Share Growth Rate was -71.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Titan Pharmaceuticals was 1559.70% per year. The lowest was -96.60% per year. And the median was -31.15% per year.
For the Biotechnology subindustry, Titan Pharmaceuticals's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Titan Pharmaceuticals's 3-Year Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where Titan Pharmaceuticals's 3-Year Revenue Growth Rate falls into.
This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
Titan Pharmaceuticals (NAS:TTNP) 3-Year Revenue Growth Rate Explanation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.
Thank you for viewing the detailed overview of Titan Pharmaceuticals's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Seow Gim Shen | 10 percent owner | NO. 4, FRANKY BUILDING, PROVIDENCE INDUSTRIAL ESTATE, MAHE T2 00000 |
Sire Group Ltd. | 10 percent owner | NO. 4, FRANKY BUILDING, PROVIDENCE INDUSTRIAL ESTATE, MAHE T2 00000 |
David Natan | director | 11190 BISCAYNE BLVD, MIAMI FL 33181 |
Matthew Charles Mcmurdo | director | 1047 SEWARD AVE., WESTFIELD NJ 07090 |
Peter Louis Chasey | director | 3295 N. FORT APACHE ROAD, STE. 110, LAS VEGAS NV 89129 |
Eric Howard Greenberg | director | 710 CARLYLE ST, WOODMERE NY 11598 |
Avraham Ben-tzvi | director | 44 ZAYT SHEMEN ST., FLAT 4, EFRAT L3 9045544 |
Katherine Beebe | director, officer: President and COO | 400 OYSTER POINT BLVD, SUITE 505, SOUTH SAN FRANCISCO CA 94080 |
Choon Hau Choong | 10 percent owner | NO. 23 LORONG TERUBONG RIA 2,, PAYA TERUBONG, GEORGE TOWN N8 11060 |
David E. Lazar | director, 10 percent owner, officer: Chief Executive Officer | VILLA 1, 14-43RD STREET, JUMEIRAH 2, DUBAI C0 00000 |
Activist Investing Llc | other: Member of 10% owner group | 1185 AVENUE OF THE AMERICAS, 3RD FLOOR., NEW YORK NY 10036 |
Joseph A Akers | director | 630 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10111 |
James R Mcnab | director | C/O CURIS, INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421 |
Marc Rubin | director, officer: Executive Chairman | C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080 |
Dane Hallberg | officer: See Remarks | 400 OYSTER POINT BLVD., SUITE 505, SOUTH SAN FRANCISCO CA 94080 |
From GuruFocus
By PRNewswire PRNewswire • 01-15-2021
By PRNewswire PRNewswire • 12-16-2020
By GuruFocusNews GuruFocusNews • 06-20-2022
By Marketwired • 07-27-2023
By PRNewswire PRNewswire • 02-01-2021
By PRNewswire PRNewswire • 11-05-2021
By PRNewswire PRNewswire • 11-16-2020
By PRNewswire PRNewswire • 07-05-2022
By GuruFocusNews GuruFocusNews • 06-30-2022
By PRNewswire PRNewswire • 06-23-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.